Inhibitors in the Management of Patients with Atherosclerotic Cardiovascular Diseases: Guidelines and Reimbursement Issues
Current guidelines for the management of patients with dyslipidemia define low-density lipoprotein cholesterol (LDL-C) as the primary target in addressing lipid-lowering therapy. The target level of LDL-C in real clinical practice is achieved in no more than a third of patients who have undergone a...
| Egile Nagusiak: | , , , , , |
|---|---|
| Formatua: | Artikulua |
| Hizkuntza: | English |
| Argitaratua: |
Столичная издательская компания
2020-09-01
|
| Saila: | Рациональная фармакотерапия в кардиологии |
| Gaiak: | |
| Sarrera elektronikoa: | https://www.rpcardio.online/jour/article/view/2264 |